Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 57 citing articles:

Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Ewgenij Proschak, Holger Stark, Daniel Merk
Journal of Medicinal Chemistry (2018) Vol. 62, Iss. 2, pp. 420-444
Closed Access | Times Cited: 410
Donepezil-based multi-functional cholinesterase inhibitors for treatment of Alzheimer's disease
Qi Li, Siyu He, Yao Chen, et al.
European Journal of Medicinal Chemistry (2018) Vol. 158, pp. 463-477
Closed Access | Times Cited: 173
Cannabinoids and Cannabinoid Receptors: The Story so Far
Fred Shahbazi, Victoria Grandi, Abhinandan Banerjee, et al.
iScience (2020) Vol. 23, Iss. 7, pp. 101301-101301
Open Access | Times Cited: 160
Targeting Cannabinoid Receptors: Current Status and Prospects of Natural Products
Dongchen An, Steve Peigneur, Louise Antonia Hendrickx, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 14, pp. 5064-5064
Open Access | Times Cited: 159
Alzheimer's disease: Updated multi-targets therapeutics are in clinical and in progress
Zhipei Sang, Keren Wang, Jianghong Dong, et al.
European Journal of Medicinal Chemistry (2022) Vol. 238, pp. 114464-114464
Closed Access | Times Cited: 85
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
Claudia Albertini, Alessandra Salerno, Pedro de Sena Murteira Pinheiro, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 5, pp. 2606-2633
Closed Access | Times Cited: 127
DARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
István Ujváry, Rachel Christie, Michael Evans‐Brown, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 7, pp. 1072-1092
Closed Access | Times Cited: 84
Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism
Shuaishuai Xing, Qi Li, Baichen Xiong, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 2, pp. 858-901
Closed Access | Times Cited: 73
A Comprehensive Review of Cholinesterase Modeling and Simulation
Danna De Boer, Nguyet Minh Nguyen, Jia Mao, et al.
Biomolecules (2021) Vol. 11, Iss. 4, pp. 580-580
Open Access | Times Cited: 72
Highly Potent and Selective Butyrylcholinesterase Inhibitors for Cognitive Improvement and Neuroprotection
Qi Li, Ying Chen, Shuaishuai Xing, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 10, pp. 6856-6876
Closed Access | Times Cited: 59
Arylazobenzimidazoles: versatile visible-light photoswitches with tuneable Z-isomer stability
Sophie A. M. Steinmüller, Magdalena Odaybat, Giulia Galli, et al.
Chemical Science (2024) Vol. 15, Iss. 14, pp. 5360-5367
Open Access | Times Cited: 8
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities
Damijan Knez, Nicolas Coquelle, Anja Pišlar, et al.
European Journal of Medicinal Chemistry (2018) Vol. 156, pp. 598-617
Closed Access | Times Cited: 82
Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer’s Disease Mouse Model
Matthias Hoffmann, Carina Stiller, Erik Endres, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 20, pp. 9116-9140
Closed Access | Times Cited: 73
Butyrylcholinesterase: A Multifaceted Pharmacological Target and Tool
Zhe Ying Ha, Shintu Mathew, Keng Yoon Yeong
Current Protein and Peptide Science (2019) Vol. 21, Iss. 1, pp. 99-109
Open Access | Times Cited: 71
7-O-Esters of taxifolin with pronounced and overadditive effects in neuroprotection, anti-neuroinflammation, and amelioration of short-term memory impairment in vivo
Sandra Gunesch, Matthias Hoffmann, Carolina Kiermeier, et al.
Redox Biology (2019) Vol. 29, pp. 101378-101378
Open Access | Times Cited: 67
Discovery of Novel Fungal Lanosterol 14α-Demethylase (CYP51)/Histone Deacetylase Dual Inhibitors to Treat Azole-Resistant Candidiasis
Guiyan Han, Na Liu, Chenglan Li, et al.
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 10, pp. 5341-5359
Closed Access | Times Cited: 58
Development of benzimidazole-based derivatives as antimicrobial agents and their synergistic effect with colistin against gram-negative bacteria
Eman M.E. Dokla, Nader S. Abutaleb, Sandra N. Milik, et al.
European Journal of Medicinal Chemistry (2019) Vol. 186, pp. 111850-111850
Closed Access | Times Cited: 57
Polypharmacological Approaches for CNS Diseases: Focus on Endocannabinoid Degradation Inhibition
Alessandro Papa, Silvia Pasquini, Chiara Contri, et al.
Cells (2022) Vol. 11, Iss. 3, pp. 471-471
Open Access | Times Cited: 29
Benzimidazole and Benzoxazole Derivatives Against Alzheimer's Disease
Nagihan Faydalı, Özlem Temiz‐Arpacı
Chemistry & Biodiversity (2024) Vol. 21, Iss. 6
Closed Access | Times Cited: 6
Cholinesterase and carboxylesterase inhibitors as pharmacological agents
Галина Ф. Махаева, Елена В. Рудакова, N. V. Kovaleva, et al.
Russian Chemical Bulletin (2019) Vol. 68, Iss. 5, pp. 967-984
Closed Access | Times Cited: 48
Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors
Lanlan Jing, Gaochan Wu, Dongwei Kang, et al.
Drug Discovery Today (2018) Vol. 24, Iss. 2, pp. 629-635
Closed Access | Times Cited: 47
Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo
Matthias Scheiner, Dominik Dolles, Sandra Gunesch, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 20, pp. 9078-9102
Open Access | Times Cited: 43
Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model
Philipp Spatz, Sophie A. M. Steinmüller, Anna Tutov, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 9, pp. 6414-6435
Open Access | Times Cited: 14
The pathomimetic oAβ25–35 model of Alzheimer's disease: Potential for screening of new therapeutic agents
Geoffrey Canet, Charleine Zussy, Célia Hernandez, et al.
Pharmacology & Therapeutics (2023) Vol. 245, pp. 108398-108398
Open Access | Times Cited: 13
Reasonably activating Nrf2: A long-term, effective and controllable strategy for neurodegenerative diseases
Qi Li, Shuaishuai Xing, Ying Chen, et al.
European Journal of Medicinal Chemistry (2019) Vol. 185, pp. 111862-111862
Closed Access | Times Cited: 37
Page 1 - Next Page

Scroll to top